뉴스벤징가
ArriVent BioPharma Lung Cancer Drug Fails Primary Trial Endpoint, Stock Hits 52-Week Low
· 발표
기사 요약
ArriVent BioPharma announced its Phase 3 lung cancer trial for firmonertinib missed the primary endpoint but showed secondary benefits.
기사 원문에서 발췌했어요.
댓글 —
댓글을 불러오고 있어요…